Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016878 | 0.98 | PAOX (0.42) | APPPAOXHRH3KCNH2HTR4 | |
| SCHEMBL4018181 | 0.98 | PAOX (0.42) | APPPAOXHRH3KCNH2HTR4 | |
| SCHEMBL4020401 | 0.98 | PAOX (0.42) | APPPAOXHRH3KCNH2HTR4 | |
| SCHEMBL4018976 | 0.98 | PAOX (0.42) | APPPAOXHRH3KCNH2HTR4 | |
| SCHEMBL4014999 | 0.98 | PAOX (0.42) | APPPAOXHRH3KCNH2HTR4 | |
| SCHEMBL4020106 | 0.98 | PAOX (0.42) | APPPAOXHRH3KCNH2HTR4 | |
| SCHEMBL4018698 | 0.98 | PAOX (0.42) | APPPAOXHRH3KCNH2HTR4 | |
| SCHEMBL671899 | 0.93 | APP (0.44) | APPPAOXHRH3PTGS1PDE4A | |
| SCHEMBL118027 | 0.92 | ALDH1A1 (0.45) | APPPAOXHRH3KCNH2HTR4 | |
| SCHEMBL29023016 | 0.92 | PAOX (0.52) | APPPAOXHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856748-B1 | METAL-ORGANIC FRAMEWORK PHASE AND CRYSTALLITE SHAPE CONTROL | UNIV CALIFORNIA (US) | 2024-03-06 | — | — | EP | claimed |
| US-11850294-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2023-12-26 | — | — | US | claimed |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2022-03-17 | — | — | US | claimed |
| EP-3468715-B1 | A PROCESS FOR TREATING AN ALKYLATING CATALYST AND PRODUCING MONO-ALKYLATED AROMATIC COMPOUND | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20240327442-A1 | CONTROLLING METAL-ORGANIC FRAMEWORK MORPHOLOGY THROUGH COORDINATIVE MIMICRY | ExxonMobil Technology and Engineering Company | 2024-10-03 | — | — | US | disclosed |
| EP-4380944-A1 | CONTROLLING METAL-ORGANIC FRAMEWORK MORPHOLOGY THROUGH COORDINATIVE MIMICRY | The Regents of the University of California (US) | 2024-06-12 | — | — | EP | disclosed |
| US-11986807-B2 | Catalyst compositions and their use in aromatic alkylation processes | ExxonMobil Engineering & Technology Company (US) | 2024-05-21 | — | — | US | disclosed |
| EP-3600654-B1 | METHODS FOR REMOVING IMPURITIES FROM A HYDROCARBON STREAM AND THEIR USE IN AROMATIC ALKYLATION PROCESSES | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11951463-B2 | Catalyst compositions and their use in aromatic alkylation processes | ExxonMobil Engineering & Technology Company (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3856748-B1 | METAL-ORGANIC FRAMEWORK PHASE AND CRYSTALLITE SHAPE CONTROL | UNIV CALIFORNIA (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-112771056-B | Metal organic framework phase and crystallite shape control | 加利福尼亚大学董事会 | 2024-02-23 | — | — | CN | disclosed |
| US-20200101439-A1 | METAL-ORGANIC FRAMEWORK PHASE AND CRYSTALLITE SHAPE CONTROL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-02 | — | — | US | disclosed |
| WO-2020068996-A1 | METAL-ORGANIC FRAMEWORK PHASE AND CRYSTALLITE SHAPE CONTROL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2435531-B1 | ELECTROCHROMIC FORMULATION, METHOD FOR THE PRODUCTION THEREOF, AND ORGANIC ELECTROCHROMIC COMPONENT | SIEMENS AG (DE) | 2013-10-30 | — | — | EP | disclosed |
| EP-1085540-B1 | SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PREPARING THE SAME | SHOWA DENKO KK (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-6466421-B1 | Solid electrolytic capacitor and method for producing the same | SHOWA DENKO K.K. (JP) | 2002-10-15 | — | — | US | disclosed |
| US-6344966-B1 | ELECTRICALLY CONDUCTING POLYMER LAYER CONTAINS AS A DOPANT AN ANION OF(1) ALKOXY-SUBSTITUTED NAPHTHALENESULFONATE, (2) A HETEROCYCLIC SULFONATE, OR (3) AN ANION OF AN ALIPHATIC POLYCYCLIC COMPOUND | SHOWA DENKO K.K. (JP) | 2002-02-05 | — | — | US | disclosed |
| US-6281224-B1 | BENZALKONIUM CHLORIDE EFFECTIVE AS A PRESERVATIVE, AND TROMETHAMINE EFFECTIVE TO KEEP THE SOLUTION STABLE AND CLEAR AND LOWERS EYE IRRITATION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-08-28 | — | — | US | disclosed |
| EP-1085540-A1 | SOLID ELECTROLYTIC CAPACITOR AND METHOD FOR PREPARING THE SAME | Showa Denko K K (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0824916-A1 | PRANOPROFEN EYEDROPS CONTAINING ORGANIC AMINE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850294-B2 | Buffered microencapsulated compositions and methods | CHMP4B, LIPA, APOB | APP 843/4885PAOX 1390/4885HRH3 3256/4885 |
| US-20240327442-A1 | CONTROLLING METAL-ORGANIC FRAMEWORK MORPHOLOGY THROUGH COORDINATIVE MIMICRY | TPR, CA4, CA2 | APP 4318/4885PAOX 197/4885HRH3 1577/4885 |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | CHMP4B, LIPA, APOB | APP 843/4885PAOX 1390/4885HRH3 3256/4885 |
| US-20200101439-A1 | METAL-ORGANIC FRAMEWORK PHASE AND CRYSTALLITE SHAPE CONTROL | POF1B, BMX, MB | APP 4448/4885PAOX 1147/4885HRH3 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.